Do analysts prefer MIRA or APRE?

Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 448.81%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than MIRA Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MIRA Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Is APRE or KALA more profitable?

KALA BIO has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat KALA BIO's return on equity. Company Net Margins Return on Equity Return on Assets Aprea Therapeutics -4,405.59% -61.03% -50.24% KALA BIO N/A -1,336.10% -94.85%

Does the media favor GOSS or APRE?

In the previous week, Gossamer Bio had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Gossamer Bio and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.98 beat Gossamer Bio's score of 0.24 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gossamer Bio 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SCYX or APRE?

In the previous week, SCYNEXIS and SCYNEXIS both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 0.98 beat SCYNEXIS's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SCYNEXIS 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Aprea Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Aprea Therapeutics (APRE) Competitors

$0.74 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$0.78 +0.04 (+5.26%)

As of 07/2/2026 07:53 PM Eastern

Compare

APRE vs. MIRA, KALA, GOSS, SCYX, and ACTU

Should you buy Aprea Therapeutics stock or one of its competitors? MarketBeat compares Aprea Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aprea Therapeutics include MIRA Pharmaceuticals (MIRA), KALA BIO (KALA), Gossamer Bio (GOSS), SCYNEXIS (SCYX), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry.

How does Aprea Therapeutics compare to MIRA Pharmaceuticals?

MIRA Pharmaceuticals (NASDAQ:MIRA) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

MIRA Pharmaceuticals has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market.

Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 448.81%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than MIRA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MIRA Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

35.2% of MIRA Pharmaceuticals shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 6.7% of MIRA Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

MIRA Pharmaceuticals has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat MIRA Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MIRA Pharmaceuticals	N/A	-140.82%	-135.01%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

In the previous week, Aprea Therapeutics had 1 more articles in the media than MIRA Pharmaceuticals. MarketBeat recorded 1 mentions for Aprea Therapeutics and 0 mentions for MIRA Pharmaceuticals. Aprea Therapeutics' average media sentiment score of 0.98 beat MIRA Pharmaceuticals' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
MIRA Pharmaceuticals	Neutral
Aprea Therapeutics	Positive

MIRA Pharmaceuticals has higher earnings, but lower revenue than Aprea Therapeutics. MIRA Pharmaceuticals is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MIRA Pharmaceuticals	N/A	N/A	-$10.44M	-$1.30	N/A
Aprea Therapeutics	$290K	31.63	-$12.60M	-$1.54	N/A

Summary

Aprea Therapeutics beats MIRA Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to KALA BIO?

Aprea Therapeutics (NASDAQ:APRE) and KALA BIO (NASDAQ:KALA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, dividends, earnings, media sentiment, risk and profitability.

Aprea Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market. Comparatively, KALA BIO has a beta of -2.35, indicating that its share price is 335% less volatile than the broader market.

Aprea Therapeutics has higher revenue and earnings than KALA BIO. Aprea Therapeutics is trading at a lower price-to-earnings ratio than KALA BIO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	$290K	31.63	-$12.60M	-$1.54	N/A
KALA BIO	N/A	N/A	-$26.98M	-$96.14	N/A

In the previous week, Aprea Therapeutics had 1 more articles in the media than KALA BIO. MarketBeat recorded 1 mentions for Aprea Therapeutics and 0 mentions for KALA BIO. Aprea Therapeutics' average media sentiment score of 0.98 beat KALA BIO's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Positive
KALA BIO	Neutral

34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 24.6% of KALA BIO shares are held by institutional investors. 10.5% of Aprea Therapeutics shares are held by company insiders. Comparatively, 2.2% of KALA BIO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

KALA BIO has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat KALA BIO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
KALA BIO	N/A	-1,336.10%	-94.85%

Aprea Therapeutics presently has a consensus target price of $4.07, suggesting a potential upside of 448.81%. KALA BIO has a consensus target price of $1,018.75, suggesting a potential upside of 60,539.88%. Given KALA BIO's higher probable upside, analysts plainly believe KALA BIO is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
KALA BIO	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Aprea Therapeutics beats KALA BIO on 12 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Gossamer Bio?

Gossamer Bio (NASDAQ:GOSS) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Gossamer Bio has a net margin of -324.82% compared to Aprea Therapeutics' net margin of -4,405.59%. Gossamer Bio's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gossamer Bio	-324.82%	N/A	-96.10%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Gossamer Bio currently has a consensus target price of $4.50, suggesting a potential upside of 2,498.15%. Aprea Therapeutics has a consensus target price of $4.07, suggesting a potential upside of 448.81%. Given Gossamer Bio's higher possible upside, research analysts clearly believe Gossamer Bio is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gossamer Bio	2 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 3.7% of Gossamer Bio shares are owned by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Gossamer Bio has a beta of 2.04, meaning that its stock price is 104% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Aprea Therapeutics has lower revenue, but higher earnings than Gossamer Bio. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gossamer Bio	$48.47M	0.84	-$170.37M	-$0.79	N/A
Aprea Therapeutics	$290K	31.63	-$12.60M	-$1.54	N/A

In the previous week, Gossamer Bio had 2 more articles in the media than Aprea Therapeutics. MarketBeat recorded 3 mentions for Gossamer Bio and 1 mentions for Aprea Therapeutics. Aprea Therapeutics' average media sentiment score of 0.98 beat Gossamer Bio's score of 0.24 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gossamer Bio	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gossamer Bio beats Aprea Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Aprea Therapeutics compare to SCYNEXIS?

SCYNEXIS (NASDAQ:SCYX) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

SCYNEXIS presently has a consensus target price of $24.00, indicating a potential upside of 441.76%. Aprea Therapeutics has a consensus target price of $4.07, indicating a potential upside of 448.81%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than SCYNEXIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SCYNEXIS	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

SCYNEXIS has a net margin of -41.79% compared to Aprea Therapeutics' net margin of -4,405.59%. SCYNEXIS's return on equity of -57.16% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SCYNEXIS	-41.79%	-57.16%	-39.48%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

54.4% of SCYNEXIS shares are held by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are held by institutional investors. 4.1% of SCYNEXIS shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

SCYNEXIS has higher revenue and earnings than Aprea Therapeutics. SCYNEXIS is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SCYNEXIS	$20.60M	2.14	-$8.61M	-$3.84	N/A
Aprea Therapeutics	$290K	31.63	-$12.60M	-$1.54	N/A

In the previous week, SCYNEXIS and SCYNEXIS both had 1 articles in the media. Aprea Therapeutics' average media sentiment score of 0.98 beat SCYNEXIS's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SCYNEXIS	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aprea Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SCYNEXIS has a beta of 1.11, meaning that its stock price is 11% more volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, meaning that its stock price is 50% more volatile than the broader market.

Summary

Aprea Therapeutics beats SCYNEXIS on 9 of the 15 factors compared between the two stocks.

How does Aprea Therapeutics compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Aprea Therapeutics (NASDAQ:APRE) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, media sentiment, valuation, dividends, analyst recommendations, earnings, profitability and institutional ownership.

34.2% of Aprea Therapeutics shares are held by institutional investors. 58.0% of Actuate Therapeutics shares are held by insiders. Comparatively, 10.5% of Aprea Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Actuate Therapeutics has a beta of 0.67, indicating that its share price is 33% less volatile than the broader market. Comparatively, Aprea Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Actuate Therapeutics has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aprea Therapeutics' return on equity of -61.03% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Aprea Therapeutics has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Aprea Therapeutics	$290K	31.63	-$12.60M	-$1.54	N/A

Actuate Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 1,051.32%. Aprea Therapeutics has a consensus target price of $4.07, indicating a potential upside of 448.81%. Given Actuate Therapeutics' higher possible upside, equities research analysts clearly believe Actuate Therapeutics is more favorable than Aprea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Aprea Therapeutics had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 1 mentions for Aprea Therapeutics and 0 mentions for Actuate Therapeutics. Aprea Therapeutics' average media sentiment score of 0.98 beat Actuate Therapeutics' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Actuate Therapeutics	Neutral
Aprea Therapeutics	Positive

Summary

Aprea Therapeutics beats Actuate Therapeutics on 11 of the 15 factors compared between the two stocks.

Get Aprea Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APRE vs. The Competition

Export

Metric	Aprea Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$9.18M	$3.78B	$7.16B	$12.48B
Dividend Yield	N/A	2.16%	2.66%	6.52%
P/E Ratio	-0.48	21.61	28.02	24.70
Price / Sales	31.63	340.22	540.55	99.42
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	0.49	8.66	10.96	6.46
Net Income	-$12.60M	$23.81M	$3.57B	$337.01M
7 Day Performance	-6.20%	3.39%	2.12%	1.69%
1 Month Performance	-0.05%	10.81%	5.25%	3.81%
1 Year Performance	-57.66%	62.61%	33.29%	23.90%

Aprea Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APRE Aprea Therapeutics	4.0286 of 5 stars	$0.74 flat	$4.07 +448.8%	-57.7%	$9.18M	$290K	N/A	7	Positive News Short Interest Decrease
MIRA MIRA Pharmaceuticals	0.7087 of 5 stars	$0.95 -0.3%	N/A	-19.6%	$39.90M	N/A	N/A	2
KALA KALA BIO	2.2254 of 5 stars	$1.73 -17.2%	$1,018.75 +58,787.3%	-99.4%	$38.85M	N/A	N/A	30	Gap Up High Trading Volume
GOSS Gossamer Bio	3.0293 of 5 stars	$0.17 +1.8%	$4.50 +2,594.6%	-85.9%	$38.49M	$48.47M	N/A	180	Gap Down
SCYX SCYNEXIS	2.4447 of 5 stars	$4.07 +5.2%	$24.00 +489.7%	-24.2%	$38.43M	$20.60M	N/A	60	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APRE) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aprea Therapeutics (APRE) Competitors

APRE vs. MIRA, KALA, GOSS, SCYX, and ACTU

How does Aprea Therapeutics compare to MIRA Pharmaceuticals?

Summary

How does Aprea Therapeutics compare to KALA BIO?

Summary

How does Aprea Therapeutics compare to Gossamer Bio?

Summary

How does Aprea Therapeutics compare to SCYNEXIS?

Summary

How does Aprea Therapeutics compare to Actuate Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aprea Therapeutics (APRE) Competitors

APRE vs. MIRA, KALA, GOSS, SCYX, and ACTU

How does Aprea Therapeutics compare to MIRA Pharmaceuticals?

Which has more volatility and risk, MIRA or APRE?

Do analysts prefer MIRA or APRE?

Do insiders & institutionals hold more shares of MIRA or APRE?

Is MIRA or APRE more profitable?

Does the media prefer MIRA or APRE?

Which has stronger valuation and earnings, MIRA or APRE?

Summary

How does Aprea Therapeutics compare to KALA BIO?

Which has more risk & volatility, APRE or KALA?

Which has better earnings & valuation, APRE or KALA?

Does the media favor APRE or KALA?

Do institutionals and insiders believe in APRE or KALA?

Is APRE or KALA more profitable?

Do analysts rate APRE or KALA?

Summary

How does Aprea Therapeutics compare to Gossamer Bio?

Is GOSS or APRE more profitable?

Do analysts recommend GOSS or APRE?

Do institutionals & insiders hold more shares of GOSS or APRE?

Which has more risk & volatility, GOSS or APRE?

Which has higher valuation and earnings, GOSS or APRE?

Does the media favor GOSS or APRE?

Summary

How does Aprea Therapeutics compare to SCYNEXIS?

Do analysts recommend SCYX or APRE?

Is SCYX or APRE more profitable?

Do institutionals and insiders have more ownership in SCYX or APRE?

Which has stronger earnings and valuation, SCYX or APRE?

Does the media favor SCYX or APRE?

Which has more risk and volatility, SCYX or APRE?

Summary

How does Aprea Therapeutics compare to Actuate Therapeutics?

Do institutionals and insiders have more ownership in ACTU or APRE?

Which has more volatility & risk, ACTU or APRE?

Is ACTU or APRE more profitable?

Which has higher valuation & earnings, ACTU or APRE?

Do analysts prefer ACTU or APRE?

Does the media refer more to ACTU or APRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APRE vs. The Competition

Aprea Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools